Spots Global Cancer Trial Database for ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Official Title: A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Study ID: NCT04044859
Study Description
Brief Summary: This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.
Detailed Description: Conditions: Endometrial Esophageal Cancer Esophagogastric Junction (EGJ) Gastric (stomach) Head and Neck Melanoma Non-small Cell Lung (NSCLC) Ovarian Cancer
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Name of Institution: Orlando Health Cancer Institute, Orlando, Florida, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Washington University - School of Medicine, Saint Louis, Missouri, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Duke University Medical Center, Duke Cancer Institute, Durham, North Carolina, United States
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
M.D. Anderson Cancer Center, Houston, Texas, United States
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Cliniques Universitaires Saint-Luc, Bruxelles, , Belgium
University Hospital Antwerp, Edegem, , Belgium
Universitair Ziekenhuis Gent, Gent, , Belgium
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Hospital Universitario 12 De Octubre, Madrid, Avenida De Cordoba S/n, Spain
Clinica Universitaria de Navarra, Pio, Pamplona, Spain
Hospital Clinico de Valencia, Ibanez, Valencia, Spain
Hospital Universitario Vall d'Hebron, Barcelona, , Spain
Hospital Universitario Fundacion Jimenez Diaz, Madrid, , Spain
Hospital Universitario HM Sanchinarro CIOCC, Madrid, , Spain
Hospital Universitario Virgen del Rocio, Sevilla, , Spain
Contact Details
Name: David Hong, MD
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
